使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon. Thank you for joining us to Stereotaxis first-quarter 2026 earnings conference call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
各位下午好。感謝各位參加 Stereotaxis 2026 年第一季財報電話會議。於本次電話會議以及隨後的問答期間所發表的某些陳述,可能涉及未來事件與預期,因此構成《1995 年私人證券訴訟改革法》所界定的前瞻性陳述。
Such statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update these statements.
此類陳述涉及已知與未知的風險、不確定性及其他因素,可能導致公司未來的實際結果、表現或成就與公司管理層今日所作陳述存在重大差異。這些風險已在我們向美國證券交易委員會提交的公開文件中詳加說明,包括我們最新的 Form 10-K 或 10-Q 定期報告。我們不承擔更新此等陳述之義務。
(Operator Instructions) As a reminder, today's call is being recorded.
(接線員指示)提醒各位,今天的電話會議將被錄音。
It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.
現在我很榮幸把會議交給本次主持人——Stereotaxis 董事長兼執行長 David Fischel。
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Thank you, operator, and good afternoon, everyone. Stereotaxis has had an amazing start to this year. While our reported quarterly numbers don't yet reflect it, we're going through one of the most exciting periods in Stereotaxis' history given the amount of progress, the initial commercial green shoots of success, and the clarity on the opportunity ahead of us. These give us confidence in our overall vision reaching a new level of maturity in our near-term and long-term growth.
謝謝接線員,各位下午好。Stereotaxis 今年開局非常亮眼。雖然我們本季公布的財務數字尚未完全反映這一點,但鑑於我們取得的進展、新產品初步商業化的「綠芽」以及對未來機會的清晰認知,我們正處於 Stereotaxis 歷史上最令人振奮的時期之一。這些因素讓我們對整體願景更具信心,並相信我們的短期與長期成長正邁向更成熟的新階段。
In my prepared remarks, I'll touch upon the key areas of progress, the commercial green shoots, and the opportunities ahead of us. Kim will then review our first-quarter results, and we will open the line to questions.
在我預先準備的發言中,我將談及幾個關鍵進展領域、商業化綠芽,以及我們面前的機會。接著 Kim 將回顧第一季業績,之後我們將開放提問。
The most notable achievement of the past year has been a string of regulatory approvals in the US and Europe for an entirely new foundational ecosystem of products. While Stereotaxis has a long history, our clinical and commercial experience is nearly all with first-generation technology from 20 years ago. After spending the past eight years and over $75 million rebuilding an R&D pipeline, we brought to market an entirely new foundation of products.
過去一年最值得關注的成就,是我們在美國與歐洲接連取得監管核准,涵蓋一個全新、具基礎性意義的產品生態系。雖然 Stereotaxis 歷史悠久,但我們的臨床與商業經驗幾乎都來自 20 年前的第一代技術。在過去八年投入超過 7,500 萬美元重建研發管線後,我們將一個全新的產品基礎推向市場。
In just the past few months, we received 4 US FDA regulatory approvals for a complex surgical robot, robotically steered therapeutic and diagnostic catheters, and a digital surgery cockpit.
僅在過去幾個月,我們就取得了 4 項美國 FDA 監管核准,涵蓋一套複雜的手術機器人、由機器人導引的治療與診斷導管,以及一個數位手術駕駛艙。
Outside of the US, we received multiple approvals in Europe and China. These product approvals are not just incremental innovations, but rather we structurally change our opportunity. We essentially developed a fresh new start-up company on the shoulders of our legacy technology and funded by our legacy business.
在美國以外,我們也在歐洲與中國取得多項核准。這些產品核准並非僅是漸進式創新,而是從結構上改變了我們的機會版圖。我們等同於在既有技術的基礎上、並由既有業務資助,打造出一家全新的新創公司。
The streak of regulatory success that began last year continued in the first part of this year with two essential FDA approvals. First, in January, we received PMA approval for the MAGiC cardiac ablation catheter. Then just last month, we received FDA clearance for Synchrony, our digital surgery cockpit that introduces connectivity and intelligence to the operating room.
自去年開始的監管成功動能,在今年前段持續延伸,並取得兩項關鍵的 FDA 核准。首先,我們於 1 月獲得 MAGiC 心臟消融導管的 PMA 核准。接著就在上個月,我們的數位手術駕駛艙 Synchrony 取得 FDA 核准(clearance),為手術室帶來連結性與智慧化。
MAGiC is Stereotaxis's first proprietary therapeutic catheter and is the first ablation catheter ever to be approved by FDA, specifically for arrhythmia patients with complex congenital heart disease. The catheter strategically allows us to overcome our historical dependency on Johnson & Johnson and to participate robustly in the recurring revenue of each procedure.
MAGiC 是 Stereotaxis 第一款自有治療性導管,也是史上第一款獲 FDA 核准、且明確針對複雜先天性心臟病心律不整患者的消融導管。該導管在策略上使我們得以擺脫過去對嬌生(Johnson & Johnson)的依賴,並能更有力地參與每台手術所帶來的經常性收入。
Following regulatory approval, we recently announced that we began first MAGiC procedures at multiple US hospitals. Those procedures have gone well. The first patient treated with the catheter had complex congenital heart disease, was being cardio weekly, failed multiple attempts to be treated with manual catheters, and was now successfully treated using MAGiC, the most beautiful example for why our innovations are critical and improve lives.
在取得監管核准後,我們近期宣布已在多家美國醫院啟動首批 MAGiC 手術,且進展順利。首位使用該導管治療的病患患有複雜先天性心臟病,每週都需接受心臟科追蹤,且曾多次嘗試以手動導管治療未果;如今透過 MAGiC 成功治療。這是最美好的例子,說明我們的創新為何至關重要、並能改善生命。
The physician who did that procedure later commented, and I quote, that was the most gratifying case I've ever done. I could have never done this without robotics.
執行該手術的醫師事後評論道——我引用原話——「那是我做過最令人滿足的一個病例。沒有機器人,我不可能完成。」
Demand for MAGiC is much higher than supply, and we are rolling out the catheter in both Europe and the US in line with the manufacturing ramp. While the ramp is gradual, we are seeing meaningful progress, and our contract manufacturer still expects production to top 500 catheters a month by the end of this year.
目前對 MAGiC 的需求遠高於供給,我們正配合製造爬坡進度,在歐洲與美國同步推進導管上市。雖然爬坡是循序漸進的,但我們看到實質進展;我們的委外製造商仍預期在今年底前,月產量可超過 500 支導管。
In addition, to mitigate catheter shortages, we began selling an additional catheter in Europe that we have exclusive rights to through our collaboration with MicroPort, and we are making meaningful progress on other efforts that expand production capacity and redundancy.
此外,為緩解導管短缺,我們已在歐洲開始銷售另一款導管;該產品透過我們與微創醫療(MicroPort)的合作,由我們享有獨家權利。同時,我們在其他擴充產能與建立備援的工作上也取得實質進展。
For now, the still small contribution from our new catheters is being countered by the headwind of winding down our relationship with Johnson & Johnson. This transition is messy and makes it difficult in reported quarterly financials to observe the underlying ramp of our new disposable business. The green shoots of this new business model are very evident to us, though, and are very attractive.
就目前而言,新導管帶來的貢獻仍然偏小,且正受到我們逐步結束與嬌生合作關係所帶來的逆風抵銷。這段轉換期相當混亂,使得從已公布的季度財務數據中不易看出我們新一次性耗材業務的實際爬坡。不過,對我們而言,這種新商業模式的「綠芽」非常明顯,而且極具吸引力。
In our initial US MAGiC procedures, we are seeing disposable revenue often above $8,000 per procedure and always above $5,000. This robust razor blade business model benefits from our strategy to build a synergistic portfolio of catheters, including MAGiC, MAGiC Sweep, and mapping.
在美國初期的 MAGiC 手術中,我們觀察到每台手術的一次性耗材收入往往超過 8,000 美元,且每次都高於 5,000 美元。這種強勁的「刀片」式耗材商業模式,受益於我們打造具協同效應的導管產品組合策略,包括 MAGiC、MAGiC Sweep 以及定位(mapping)產品。
In Europe, just this month, we received an order for $100,000 in disposables from a single hospital for what it expects to be a month's worth of procedures. These amounts are in line with the EP market but are unprecedented for us. They demonstrate the transformation that is just starting to take shape in our business model, still at low numbers, but increasingly very material as we advance through this year and transition our installed base of robotic accounts over to this new ecosystem.
在歐洲,就在本月,我們收到單一醫院一次性耗材 10 萬美元的訂單,該院預期這相當於其一個月的手術用量。這些金額與電生理(EP)市場水準一致,但對我們而言前所未見。它們顯示我們商業模式的轉型才剛開始成形——目前量仍低,但隨著我們在今年持續推進、並將既有機器人客戶群逐步轉換至這個新生態系,影響將愈發顯著且具重大性。
By the end of this year, we expect to have substantially transitioned customers as they use up remaining inventory of J&J catheters, work through hospital approvals and tender processes, and gain experience with MAGiC.
我們預期在今年底前,隨著客戶逐步用完剩餘的嬌生導管庫存、完成院內核准與招標流程,並累積 MAGiC 的使用經驗,客戶轉換將在很大程度上完成。
The structural transformation to our disposable business model is taking place as we simultaneously structurally transform our capital business. This is happening primarily through the launch of GenesisX, the new robotic system that we received FDA clearance for at the end of last year and which doesn't require construction to be installed in existing catheter labs. We have a healthy pipeline of physicians and hospitals that are working towards orders for GenesisX, and we are prepared to be the first to demonstrate it installed rapidly in existing labs while working compatible with nonmodified X-rays for major X-ray manufacturers.
在一次性耗材商業模式發生結構性轉型的同時,我們也正同步推動資本設備業務的結構性轉型。這主要透過 GenesisX 的推出來實現——這是我們在去年底取得 FDA 核准(clearance)的新一代機器人系統,且可在既有導管室中安裝而無需施工。我們擁有健康的醫師與醫院管線,正朝 GenesisX 訂單推進;我們也已準備好率先示範其可在既有導管室中快速安裝,並可與主要 X 光設備製造商的未改裝 X 光系統相容運作。
Compatibility testing and commercial agreements are advancing in tandem. We continue to expect to establish at least five active GenesisX programs over the course of this year. These initial adopters and their demonstrations of the technology's accessibility, interoperability, and performance will be very beneficial in expanding adoption.
相容性測試與商業合作協議正同步推進。我們仍預期在今年內建立至少五個活躍的 GenesisX 專案。這些早期採用者及其對技術可及性、互通性與效能的展示,將有助於擴大採用。
The second significant change to our capital business is the start of a synergistic but independent capital opportunity with Synchrony and SynX. As a reminder, Synchrony and SynX are our digital solutions that modernize the interventional surgical suite with enhanced workflow, remote connectivity, and smart AI capabilities.
我們資本設備業務的第二項重大變化,是透過 Synchrony 與 SynX 開啟一個具協同效應但相對獨立的資本機會。提醒各位,Synchrony 與 SynX 是我們的數位解決方案,透過強化工作流程、遠端連線,以及智慧 AI 能力,讓介入式手術室現代化。
Just last month, we received FDA clearance for Synchrony. We have already received orders for multiple systems and have shipped the first systems to customers. We are very confident in our guidance of $3 million in revenue from Synchrony this year.
就在上個月,我們取得 Synchrony 的 FDA 核准(clearance)。我們已收到多套系統的訂單,並已將首批系統出貨給客戶。我們對今年 Synchrony 帶來 300 萬美元營收的指引非常有信心。
The initial commercial green shoots from our new product portfolio are exciting. The operational and commercial friction to ramp manufacturing and implement new products makes progress gradual, but everything is moving in the right direction, and we are efficiently driving broad-based progress on many fronts in parallel. We're doing this while weaning ourselves away from the dependencies and challenges of our legacy business. It's a tough transition, but we are building a very attractive business on solid foundations.
我們新產品組合所帶來的初步商業化綠芽令人振奮。製造爬坡與新產品導入在營運與商業面存在摩擦,使進展較為循序漸進;但一切都朝正確方向前進,我們也正以高效率在多個面向並行推動廣泛進展。同時,我們也在逐步降低對既有業務的依賴及其帶來的挑戰。這是一段艱難的轉型,但我們正以穩固的基礎打造一個極具吸引力的企業。
What is particularly exciting for me is that we aren't resting on our laurels. While the benefits of this first wave of innovation start to become operational and commercial reality, we are energetically planting the seeds for significant opportunities that will blossom over the next few years.
對我而言,特別令人振奮的是,我們並未停留在既有成就上。當這第一波創新帶來的效益逐步轉化為營運與商業現實之際,我們也正積極播下種子,為未來幾年將綻放的重大機會做準備。
Our vision for what Stereotaxis can and will accomplish is becoming increasingly clear and tangible. That vision can be summarized as follows: our core mission is to pioneer robotics across endovascular surgery.
我們對 Stereotaxis 能夠、也將要達成的願景正變得愈發清晰且具體。該願景可總結如下:我們的核心使命,是在血管內手術領域開創機器人技術。
That means building fantastic robots that enable what is otherwise impossible, improving patient outcomes and physician experiences. It means these robots should be fully mobile, unintrusive, interoperable, and accessible. It means robots that can do the full range of activity necessary across the breadth of endovascular procedures, EP, neuro, cardiac, and peripheral, with a matching portfolio of advanced interventional devices. It means embedding these robots with digital innovation such that they not only mechanically manipulate devices, but also add intelligence, connectivity, and automation to make procedures smarter, better, and quicker.
這意味著打造卓越的機器人,讓原本不可能的事情成為可能,並改善病患預後與醫師的使用體驗。這意味著這些機器人應該完全可移動、不具侵入性、可互通且易於取得。這意味著機器人能在血管內介入手術、電生理(EP)、神經、心臟與周邊等廣泛領域中,執行所需的完整活動範圍,並搭配相應的先進介入器械產品組合。這也意味著將數位創新嵌入這些機器人之中,使其不僅能以機械方式操控器械,還能加入智慧、連結性與自動化,讓手術更聰明、更好且更快速。
This isn't an idle vision. We established a solid foundation for it with our initial portfolio of products. We have also been advancing in the background multiple efforts to realize the full vision. A few examples.
這不是空想的願景。我們以最初的產品組合為此建立了堅實基礎。我們也在幕後推進多項工作,以實現完整願景。舉幾個例子。
First, at the European Heart Rhythm Association Conference last month, we showed up a future generation of the GenesisX robot that is fully wireless, battery-operated, and mobile. We've invested in this project for a few years, and it is moving along well. In the future, all our robotic platforms will be fully mobile and wireless.
第一,在上個月的歐洲心律協會(European Heart Rhythm Association)年會上,我們展示了下一代 GenesisX 機器人的雛形:完全無線、電池供電且可移動。我們已在此專案投入數年,目前進展良好。未來,我們所有的機器人平台都將完全可移動且無線。
Second, we are busy at work with two significant AI efforts, one for decision support AI features incorporated into Synchrony to help physicians intraoperatively benefit from the wisdom of thousands of procedures, and the second, a rehaul of our automated navigation software, so physicians simply design the procedure, and the robot executes it. A specific project here is with a larger industry partner who sees the opportunity for automation to offer the most efficient and yet personalized patient-specific therapy.
第二,我們正積極推進兩項重要的 AI 計畫:其一是將決策支援型 AI 功能整合進 Synchrony,協助醫師在術中受益於數千例手術的智慧;其二是全面改造我們的自動導航軟體,讓醫師只需設計手術流程,機器人即可執行。此處的一個具體專案是與一家更大型的產業夥伴合作,對方看見自動化有機會提供最高效率、同時又能個人化、以病患為中心的治療。
And finally, and most significantly and transformationally, we announced the acquisition of Robocath last month, which, as mentioned at the time, gives Stereotaxis a fully complementary and separate robotic mechanism of action for endovascular device navigation. The combination of our technologies offers a clear vision for how our robotic solution, including the full ecosystem of digital innovations will enable remote, automated, and fully robotic treatment of stroke and cardiovascular disease.
最後,也是最重要且最具轉型意義的一點,我們在上個月宣布收購 Robocath。正如當時所提到的,這使 Stereotaxis 在血管內器械導航方面,獲得一套完全互補且獨立的機器人作用機制。我們技術的結合,清楚描繪了我們的機器人解決方案(包含完整的數位創新生態系)將如何實現遠端、自動化與全機器人化的中風與心血管疾病治療。
The puzzle pieces have come together in a remarkable fashion. We are fully focused on executing the key operational and commercial activities to reap the rewards from our recent regulatory approvals, grow revenue, and reach breakeven. We are simultaneously busy at work through the acquisition of Robocath, other business development activities, and in-house R&D on a robust innovation effort across robotics, interventional devices, AI, and automation. The goals, direction of the path, and stepping stones of progress along the path have become increasingly clear to us. We are energetically and enthusiastically advancing forward.
各個拼圖以令人驚豔的方式拼合在一起。我們全力聚焦於執行關鍵的營運與商業活動,以收穫近期法規核准所帶來的成果、推動營收成長並達到損益兩平。同時,我們也透過收購 Robocath、其他業務開發活動,以及內部研發(R&D),在機器人、介入器械、AI 與自動化等領域推進強勁的創新計畫。我們對目標、路徑方向,以及沿途的里程碑與進展階梯,已愈來愈清晰。我們正以充沛的能量與熱情持續向前推進。
Kim will now provide commentary on our financial results, and then I'll make a few financial comments as well before opening the call to Q&A. Kim?
接下來 Kim 將就我們的財務結果提供評論,之後在開放問答(Q&A)之前,我也會補充幾點財務方面的看法。Kim?
Kimberly Peery - Chief Financial Officer
Kimberly Peery - Chief Financial Officer
Thank you, David, and good afternoon, everyone. Revenue for the first quarter of 2026 totaled $6.3 million compared to $7.5 million in the prior year's first quarter. System revenue of $1.3 million and recurring revenue of $5 million compared to $2 million and $5.5 million in the prior year's first quarter. System revenue in the current quarter reflects revenue recognition on the installation of one Genesis system and partial revenue recognition of other ancillary systems. Recurring revenue in the quarter was pressured by the transition from the Johnson & Johnson ecosystem.
謝謝你,David,各位下午好。2026 年第一季營收合計 630 萬美元,較去年第一季的 750 萬美元下降。系統營收為 130 萬美元、經常性營收為 500 萬美元,相較去年第一季分別為 200 萬美元與 550 萬美元。本季系統營收反映了一套 Genesis 系統安裝的收入認列,以及其他附屬系統的部分收入認列。本季經常性營收受到從 Johnson & Johnson 生態系轉換的影響而承壓。
Gross margin for the first quarter of 2026 was 60% of revenue. Recurring revenue gross margin was 66%, and system gross margin was 39%. Operating expenses in the quarter of $9.8 million included $3.1 million in noncash charges for stock compensation expense, mark-to-market adjustment for acquisition-related contingent earnout consideration, and amortization of acquired intangibles. Excluding these noncash charges, adjusted operating expenses were $6.7 million, similar to the prior year adjusted operating expenses of $6.8 million.
2026 年第一季毛利率為營收的 60%。其中,經常性營收毛利率為 66%,系統毛利率為 39%。本季營業費用為 980 萬美元,包含 310 萬美元的非現金費用,涵蓋股票酬勞費用、與收購相關之或有對價(earnout)按市價評價調整,以及收購無形資產攤銷。排除這些非現金費用後,調整後營業費用為 670 萬美元,與去年調整後營業費用 680 萬美元相近。
Operating loss and net loss in the first quarter of 2026 were $6 million and $5.9 million compared with $5.9 million and $5.8 million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding noncash charges, were $2.9 million and $2.8 million compared with $2.7 million and $2.6 million in the previous year. Negative free cash flow for the first quarter was $3.5 million compared to $1.8 million in the previous year. At March 31, Stereotaxis had cash and cash equivalents of $14.6 million and no debt.
2026 年第一季營業損失與淨損失分別為 600 萬美元與 590 萬美元,去年同期分別為 590 萬美元與 580 萬美元。排除非現金費用後,本季調整後營業損失與調整後淨損失分別為 290 萬美元與 280 萬美元,去年同期分別為 270 萬美元與 260 萬美元。第一季自由現金流為負 350 萬美元,去年同期為負 180 萬美元。截至 3 月 31 日,Stereotaxis 持有現金及約當現金 1,460 萬美元,且無負債。
I will now hand the call back to David.
我現在把電話交回給 David。
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Thank you, Kim. I want to conclude by emphasizing that while not yet reflected in our quarterly financial results, the commercial green shoots I mentioned previously have begun. Over the coming months, the positive impact will grow in momentum and overshadow the pressures on our legacy business.
謝謝你,Kim。我想在結語中強調,雖然這些尚未反映在我們的季度財務結果中,但我先前提到的商業面「綠芽」已經開始出現。在接下來幾個月,正面影響將持續累積動能,並蓋過我們既有業務所面臨的壓力。
We are reiterating our revenue guidance for the year of double-digit revenue growth, with annual revenue expected to surpass $40 million. Revenue will ramp up sequentially each quarter, and we expect both the third and fourth quarters of this year to have revenue of above $10 million a quarter.
我們重申今年的營收指引為兩位數的營收成長,全年營收預期將超過 4,000 萬美元。營收將逐季爬升,我們預期今年第三季與第四季的單季營收都將高於 1,000 萬美元。
From a financial perspective, we're confident that we can advance our strategy, integrate Robocath, and grow significantly without subjecting investors to substantial dilution. Operating losses will be reduced as we grow recurring revenue, with the majority of recurring revenue dropping to the bottom line.
從財務角度來看,我們有信心在不讓投資人承受顯著稀釋的情況下,推進我們的策略、整合 Robocath,並實現顯著成長。隨著經常性營收成長,營業損失將降低,且大部分經常性營收將直接反映至最終獲利(bottom line)。
We have opportunistically taken advantage of the ATM at prices significantly higher than our current valuation, with overall minimal dilution, strengthening our balance sheet, and bridging us through the acquisition of Robocath and the time needed to build momentum with recurring revenue.
我們把握時機在價格顯著高於目前估值的水準下,透過 ATM(隨市發行)進行籌資,整體稀釋幅度極小,強化了資產負債表,並讓我們得以支應 Robocath 的收購,以及建立經常性營收成長動能所需的時間。
We have invested significantly in inventory that supports meaningful GenesisX and Synchrony revenue and maintain a clean balance sheet. And we continue to pursue strategic opportunities for non-dilutive non-debt financing. It is a delicate balancing act, and there is much being done in parallel, but we feel comfortable with our balance sheet, allowing us to advance our innovation strategy to market, fund the commercial ramp, and achieve profitability.
我們已在支援 GenesisX 與 Synchrony 具規模營收的庫存上投入可觀資金,並維持乾淨的資產負債表。同時,我們持續尋求策略性機會,以取得非稀釋、非負債的融資。這是一項精細的平衡,且有許多工作同時並行,但我們對資產負債表狀況感到安心,這使我們能將創新策略推向市場、資助商業放量(commercial ramp),並達成獲利。
We'll now take your questions. Operator, can you please open the line to Q&A.
接下來我們將回答各位的問題。接線員,請開放問答(Q&A)線路。
Operator
Operator
(Operator Instructions) Danny Stauder, Citizens.
(接線員指示)Danny Stauder,Citizens。
Daniel Stauder - Analyst
Daniel Stauder - Analyst
Yeah, great. Thanks for taking the questions. So just for my first one on catheters. You mentioned some initial green shoots, and I know it's still early days, but for your customers that have started to use the MAGiC portfolio, I know you commented you're seeing revenue per procedure above $5,000, sometimes around $8,000, which is great to hear. But I was just curious if you could give us more color here, specifically in terms of how sticky utilization has been for new users of MAGiC? And are you seeing a pretty immediate uptick following adoption? Does it take time to ramp? Any more commentary would be great. Thank you.
好的,很棒。謝謝讓我提問。那我第一個問題是關於導管。你提到一些初步的「綠芽」,我也知道目前仍在早期階段,但對於已開始使用 MAGiC 產品組合的客戶,我知道你提到你們看到每例手術的營收高於 5,000 美元,有時約 8,000 美元,這很令人振奮。不過我想更深入了解,特別是:對於 MAGiC 的新使用者而言,使用量的黏著度如何?採用後是否會很快看到使用量上升?還是需要時間爬坡?若能提供更多說明將非常感謝。謝謝。
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Sure. Hi, Danny. Good afternoon. So MAGiC adoption is right now still limited by production capacity. So we have sites that would like to transition 100% over. We have sites that have tried it and still have J&J catheters and are kind of for a period would like to use both and gradually transition. And we have sites that have stayed only with J&J at this point, but know that they have to transition over the coming months. And so really kind of all of our sites fall into one of those three buckets.
當然。嗨,Danny,下午好。目前 MAGiC 的採用仍受限於產能。因此,我們有一些院所希望 100% 全面轉換;也有一些院所已試用,但仍保有 J&J 的導管,並希望在一段期間內兩者並行使用、逐步轉換;另外也有一些院所目前仍只使用 J&J,但也知道未來幾個月必須轉換。所以基本上,我們所有院所大致都落在這三種類型之一。
Right now, we're still capacity constrained, and so that is the main barrier. There will be sites where as manufacturing continues to ramp, and it is getting better as the weeks go on. But as manufacturing continues to ramp, there will be sites that they've completely shifted over and every procedure they do will be with MAGiC, MAGiC Sweep, mapping kind of our ecosystem of catheters.
目前我們仍受到產能限制,因此這是主要障礙。隨著製造持續爬坡,而且每週都在改善,將會有一些院所完全轉換,之後他們每一台手術都會使用 MAGiC、MAGiC Sweep,以及我們導管生態系中的 mapping(定位/標測)等產品。
There are other sites that will likely run things side by side for a period of time. And then there's others, like I mentioned, that kind of will stay in the J&J ecosystem as long as they can. But essentially, they all know that over the coming months, probably over the next year, they essentially have to transition given the availability of J&J catheters. And so that kind of will drive a transition point.
也有其他院所可能會在一段時間內採取並行方式運作。然後還有一些,如我提到的,會盡可能久地留在 J&J 生態系。但本質上,他們都知道在接下來幾個月、可能在未來一年內,基於 J&J 導管的供應情況,他們基本上必須完成轉換。因此,這將推動一個轉換的時間點。
And so we're working -- really, it's a ground game account by account to get them over that transition to get them comfortable and working well with MAGiC and the whole new ecosystem and then kind of comfortable to start ordering MAGiC in a robust fashion as they've shifted over.
因此我們正在努力——坦白說,這是一場逐戶推進的地面戰,一個帳戶一個帳戶地協助他們完成轉換,讓他們對 MAGiC 以及整個全新生態系感到安心並能順利運作,接著在他們完成轉換後,逐步建立信心,開始以更具規模的方式下單採購 MAGiC。
Daniel Stauder - Analyst
Daniel Stauder - Analyst
Okay, great. And then just one follow-up for me on that. Just as we look at the quarter's results and your reiteration of guidance, I was hoping you could give us a little bit more on what is assumed in reaching that $40 million-plus number in terms of the timing of manufacturing improvement. I know you still called out the 500 monthly catheter metric by year-end, but have you seen a meaningful shift in catheter production yield or any notable trends since the end of March? And how should we be thinking about some of these headwinds in the second quarter? And really here, just trying to get a sense of how confident you are in the continued improvement throughout the year on this front. Thank you.
好的,很好。接著我還有一個追問。就本季的業績以及你們重申的財測指引來看,我希望你們能多談一點:為了達到 4,000 萬美元以上這個數字,在製造改善的時程假設上是怎麼設定的。我知道你們仍提到年底要達到每月 500 支導管的指標,但自 3 月底以來,你們是否看到導管生產良率有明顯變化,或有任何值得注意的趨勢?另外,我們應該如何看待第二季的一些逆風?我主要是想了解你們對於今年內在這方面持續改善的信心程度。謝謝。
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Yeah. Sure. So if you think about the ASPs that our catheter portfolio provides and you think that we're working towards 500 catheters a month by the end of this year, you can do kind of back of envelope math, and you can see that the type of disposable revenue that we would have in a quarter around the end of this year is higher than all of our recurring revenue right now.
是的,當然。如果你把我們導管產品組合所帶來的平均銷售單價(ASP)納入考量,並且想到我們正朝著今年底每月 500 支導管的目標前進,你可以做一個粗略的估算,就會看到在今年底附近的某一季,我們可取得的一次性耗材收入規模,將高於我們目前所有的經常性收入總和。
And so there is a lot of benefit to the shift in business model where you actually capture the revenue per procedure. And again, this is not with charging the hospital any more than what they're used to paying. This is really just participating in the revenue that previously we didn't participate in.
因此,商業模式的轉變帶來很大的好處,因為你實際上能夠按每次手術來取得收入。再次強調,這並不是向醫院收取比他們過去支付更多的費用;而是我們開始參與到過去我們未能參與的那部分收入中。
And so that's kind of -- that's the primary driver, obviously, to revenue. And so, you can start to model things where our recurring revenue by itself is reaching the near $10 million or so level as we ramp manufacturing of catheters to that level.
所以這大致上——這顯然是收入的主要驅動因素。因此,你可以開始建立模型:當我們把導管製造爬坡到那個水準時,僅靠我們的經常性收入本身就能接近約 1,000 萬美元左右的水準。
On the system side, there's obviously, this was a particularly weak quarter from a system perspective. We still have a pipeline. We still have a backlog. We're still engaged with accounts, both on Genesis and GenesisX. I think the majority of GenesisX accounts will be in the lease plus disposable commitment category, though there are some definite opportunities for sales there. But the Genesis system is still fully a sales, and so that would be kind of revenue recognition upfront. And so that's kind of the way we're looking at the opportunity as we go through this year.
在系統端,顯然從系統角度來看,這一季特別疲弱。我們仍然有管線(pipeline),仍然有積壓訂單(backlog),也仍持續與客戶洽談,涵蓋 Genesis 與 GenesisX。我認為多數 GenesisX 客戶會落在「租賃加耗材承諾」的類別,雖然也確實存在一些直接銷售的機會。但 Genesis 系統仍完全以銷售為主,因此收入會在前期認列。這就是我們在今年推進過程中看待機會的方式。
Operator
Operator
[Adam Bader], Piper Sandler.
[Adam Bader],Piper Sandler。
Unidentified Participant
Unidentified Participant
Great. Thanks. This is Kyle on for Adam. I guess, first to dig in a little more there on the disposable business. I was wondering if you could just kind of quantify the impact in the quarter for us, just to kind of try to help us understand where these impacts are in the quarter?
很好,謝謝。我是代 Adam 提問的 Kyle。我想先更深入一點談耗材業務。我想請你們能否就本季的影響做一些量化,幫助我們理解這些影響在本季是如何體現的?
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Sure. So MAGiC and MAGiC Sweep, the MAGiC portfolio was very small in the quarter overall. I think like we mentioned in our call in March, we had very little production in January, February because they were shifting over a process in the manufacturing line to a newer process, which improved the yield significantly. And so essentially in January and February, the entire all production was meant for validating that shift in the process.
當然。MAGiC 與 MAGiC Sweep,也就是 MAGiC 產品組合,在本季整體占比非常小。我想就像我們在 3 月的電話會議中提到的,1 月、2 月的產量非常少,因為他們正在製造產線上把流程切換到一個更新的製程,而該製程大幅提升了良率。因此基本上在 1 月與 2 月,全部的產出都是用來驗證這個製程切換。
And then we did have decent production in March, but that was -- most of the revenue from that production comes into April by the time it gets produced and sterilized and shipped to us and then we can actually ship to customers and recognize revenue.
接著 3 月我們確實有不錯的產量,但——那批產量所帶來的大部分收入,會在 4 月才進來,因為從生產完成、滅菌、運送到我們這裡,然後我們才能出貨給客戶並認列收入,需要一些時間。
And so, there was very little revenue recognition in the first quarter from MAGiC and MAGiC Sweep. The primary headwind is that Johnson & Johnson has not been supplying catheters well to accounts. And so, there's obviously a pressure there in our accounts from that. And so that's kind of where the pressure on procedures from the Johnson & Johnson catheter and behavior versus the step-up in revenue from shifting procedures to the MAGiC environment. That's kind of the give and take that's happening in our disposable revenue right now.
因此,第一季來自 MAGiC 與 MAGiC Sweep 的收入認列非常少。主要逆風在於 Johnson & Johnson 對客戶端的導管供應不佳,因此我們的客戶確實因此承受壓力。所以目前在我們的耗材收入上,存在一種拉鋸:一方面是因 Johnson & Johnson 導管供應與其行為所造成的手術量壓力;另一方面則是把手術轉移到 MAGiC 環境後所帶來的收入提升。這就是我們目前耗材收入正在發生的取捨。
And again, the step-up from the MAGiC portfolio should overshadow as we start to get meaningful numbers in the second quarter, third quarter should overshadow by far any pressures that we're seeing from Johnson & Johnson.
而且再次強調,隨著我們在第二季開始取得有意義的數量,第三季更是如此,MAGiC 產品組合帶來的增量應該會遠遠蓋過我們目前從 Johnson & Johnson 看到的任何壓力。
Unidentified Participant
Unidentified Participant
Okay, great. That's helpful. And then for my follow-up, maybe on the systems side, heard some of the discussion around the pipeline and where discussions are. I was just hoping you could maybe dig in a little more if you could just give kind of more on the qualitative measures, just what's the early feedback been, what are those discussions like? And then maybe that can kind of help us understand when you expect that first order to come in for GenesisX?
好的,很好,這很有幫助。那我的追問可能是關於系統端:我聽到一些關於管線以及洽談進展的討論。我想請你們能否再深入一點,提供一些更偏質性的指標——例如早期回饋如何、這些討論大概是什麼樣子?也許這能幫助我們理解你們預期 GenesisX 的第一筆訂單何時會進來?
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Yeah, sure. So maybe I'll step back a little bit and provide again context for why this is a structural change that we are working through that is very beneficial as you come out on the other side of it but is more complicated than perhaps many people have appreciated until now.
好的,當然。也許我先退一步,再次提供一些背景,說明為什麼這是一個我們正在推進的結構性變革:它在完成後會非常有利,但過程比許多人到目前為止所理解的更複雜。
Historically, in our entire history, we have only sold our robot with an integrated magnetically modified, magnetically shielded X-ray and all of our systems to date. We have built GenesisX such that it can work compatible with non-integrated X-rays. That is a structural change that as you implement it, provides you a much, much bigger base of accounts and labs where you can place your robot, and it makes the process of installing your robot much, much easier because you're not having to always install it concurrent with a specific unique X-ray.
過去在我們整個公司歷史中,我們只銷售搭配整合式、經磁性改造且具磁性屏蔽的 X 光設備的機器人,以及迄今為止的所有系統。我們打造 GenesisX,使其能與非整合式 X 光設備相容運作。這是一項結構性改變:一旦你把它落地實施,就能讓你面向更大、更多的客戶與實驗室基礎來部署機器人;同時也讓安裝流程容易得多,因為你不必總是要與某一款特定且獨特的 X 光設備同步安裝。
And so, implementing that and making -- right, we obviously did receive our first order for GenesisX last year. We shipped the system. The system is awaiting installation at an account. That was done according to the historical model, which we'll still continue to do where we sell our robots concurrent with selling magnetically shielded and integrated X-ray. And so that's kind of how all Genesis sales are still being done.
因此,在推動這件事並讓——對,我們確實在去年收到 GenesisX 的第一筆訂單。我們已出貨該系統;該系統正在某個客戶端等待安裝。那筆交易是依照歷史模式進行的,而我們也會持續這麼做:也就是在銷售機器人的同時,搭配銷售具磁性屏蔽且整合式的 X 光設備。因此,所有 Genesis 的銷售目前仍是以這種方式進行。
That's how we did the first Genesis X shipment as well. But making Genesis X such that it can work compatibly with the broad range of X-rays from the major X-ray manufacturers is a big effort. We've done a huge amount of that effort already. We're very confident in the assessments and testing that we've done to date.
我們第一套 GenesisX 的出貨也是這樣做的。但要讓 GenesisX 能與主要 X 光製造商的廣泛 X 光設備相容運作,是一項很大的工程。我們已經完成了大量工作,並且對目前為止所做的評估與測試非常有信心。
And what we're really looking right now for the first few GenesisX systems apart from that one that we've already sold is proving the model that GenesisX can work compatible with any of the large X-ray manufacturers. And that, to some extent, opens you up to a whole world of capital opportunity that previously was not available to us.
而我們現在真正要做的是:除了那一套已經售出的系統之外,接下來的前幾套 GenesisX,要用來驗證這個模式——也就是 GenesisX 能與任何大型 X 光製造商相容運作。這在某種程度上,會為你打開一個過去我們無法觸及的、全新的資本設備機會世界。
The first users who are going to work with us in that effort are obviously, need to be physicians and hospitals who are comfortable in that type of pioneering work and in the kind of working through the uncertainty and the risk.
最早會與我們一起推進這項工作的使用者,顯然需要是願意投入這類開創性工作的醫師與醫院,並且能接受在不確定性與風險中共同推進。
We obviously, through all the kind of scientific testing, we can explain and we can document why there isn't a real risk, but there's always somewhat of a risk when you're the first ones to demonstrate something. And so we're glad that we do have accounts that are kind of open and interested in working with us to demonstrate the robot working in this nonintegrated fashion, but that's really what we're doing with these first kind of pioneering accounts that are going to start using GenesisX and serving as kind of the show places where GenesisX works in existing labs.
當然,透過各種科學測試,我們可以解釋並文件化為什麼實際上沒有真正的風險,但當你是第一批去證明某件事的人時,總是會存在某種程度的風險。因此,我們很高興確實有一些客戶願意開放並有興趣與我們合作,來示範機器人以這種非整合方式運作;而這正是我們與這些最初的「先行者」客戶所要做的事——他們將開始使用 GenesisX,並作為展示據點,證明 GenesisX 能在既有實驗室中運作。
Operator
Operator
Joshua Jennings, TD Cowen.
Joshua Jennings,TD Cowen。
Joshua Jennings - Analyst
Joshua Jennings - Analyst
Hi. Thanks, David and Kim. Appreciate taking the questions. I wanted to just ask about some of the Johnson & Johnson turbulence and just thinking about the MAGiC integration at these centers and what mapping platform are electrophysiologists using today when they integrate MAGiC into ablation case? And could there be any turbulence going forward? I mean, should we be thinking that MAGiC will be used with Carto as well as this catheter supply relationship ends with J&J?
嗨,謝謝 David 和 Kim。感謝你們回答問題。我想問一下關於 Johnson & Johnson 的一些動盪,並且從 MAGiC 在這些中心的整合角度來思考:當電生理醫師在消融手術中整合 MAGiC 時,他們目前使用的是哪一個標測平台(mapping platform)?未來是否可能還會有一些動盪?我的意思是,隨著與 J&J 的導管供應關係結束,我們是否應該預期 MAGiC 也會與 Carto 一起使用?
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Sure. So we've been committed to the concept of open ecosystems around our robot, where you can pair the benefits of our robot with a broad range of diagnostic and therapeutic technologies out there. And that has been kind of one of our commitments from the beginning to our physicians. It's the right thing for patients, for physicians, for hospitals and overall, for the progress of medicine.
當然。所以我們一直致力於圍繞我們的機器人打造開放式生態系的理念,讓您可以把我們機器人的優勢與市面上各式各樣的診斷與治療技術結合起來。而這從一開始就是我們對醫師的承諾之一。這對病人、對醫師、對醫院,以及整體醫學進步而言,都是正確的方向。
And as part of that, we integrated with Abbott's EnSite X system, its latest mapping technology, and we're fully integrated with EnSite, and that has been the predominant mapping system that is being used with MAGiC.
作為其中一部分,我們已與 Abbott 的 EnSite X 系統(其最新的標測技術)完成整合,並且與 EnSite 完全整合;而這也一直是與 MAGiC 搭配使用的主流標測系統。
There are some ways to make MAGiC work also with Carto. We also obviously have a full integration with the MicroPort mapping system, Columbus. That is not available in the US, but that is available in Europe and in China, obviously. And so there are kind of some others, but in the majority of cases and definitely in the US and mostly in Europe, you're seeing EnSite X being used with MAGiC, Abbott system.
也有一些方式可以讓 MAGiC 與 Carto 搭配運作。我們當然也與 MicroPort 的標測系統 Columbus 完全整合。該系統在美國尚未上市,但在歐洲以及中國(當然)是有的。所以還有其他一些選項,但在多數情況下,尤其是在美國以及歐洲的大部分地區,您會看到 EnSite X(Abbott 系統)與 MAGiC 搭配使用。
Joshua Jennings - Analyst
Joshua Jennings - Analyst
Thanks for those details. And also at HRS in the robotic symposium, I think two topics we were impressed with. I mean, one, just some of the progress on the PFA development. If you could just share any incremental progress today?
謝謝這些細節。另外在 HRS 的機器人專題研討會上,我想有兩個主題讓我們印象深刻。第一個是 PFA 開發的一些進展。您能否分享一下截至今天的任何新增進展?
And then also, there seems to be optimism from some electrophysiologists that are already involved in the cardiology ASCs or cardiology ambulatory procedure centers that robotics could be incorporated. Sorry for two questions in one, but maybe you could touch on both of those topics and how you see PFA evolving with the robotic platform and integrating the MAGiC catheter and then also just the opportunity in ASCs. Thanks for taking the questions.
第二個是,似乎有一些已經參與心臟科 ASCs(心臟科門診手術中心/門診處置中心)的電生理醫師對於將機器人納入其中抱持樂觀態度。抱歉一次問兩個問題,但也許您可以談談這兩個主題:您如何看待 PFA 隨著機器人平台的演進、與 MAGiC 導管的整合,以及在 ASCs 的機會。謝謝您回答問題。
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Sure. Thanks a lot. And yes, I'll definitely touch upon both PFA and the ASC setting. And maybe before that, just since you mentioned the HRS and the Society for Cardiac Robotic Navigation Symposium that happened at HRS. I mean, that was a beautiful demonstration of how the fact that we are innovating and bringing new solutions to the market does create a different level of excitement in the field.
當然。非常感謝。是的,我一定會同時談到 PFA 與 ASC 場景。在那之前,既然您提到 HRS 以及在 HRS 期間舉辦的心臟機器人導航學會(SCRN)研討會——那真的是一個很好的展示,說明我們持續創新並把新解決方案帶到市場,確實能在這個領域激發不同層次的興奮感。
There -- with all of the challenges and all of the messiness to the transition, we had at HRS about, I don't know, it was a huge room and probably about 200 or so people who came at the far end, you have to walk all the way at the end of the hallway in order to get to the room of SCRN. And right, you have probably about 200 or so people who attended that session with fantastic talks from multiple physicians and KOL physicians. And so that was kind of a really, really nice event. And I think it's reflective generally of the type of interest.
在那裡——儘管轉換過程充滿各種挑戰與混亂——我們在 HRS 的 SCRN 會場,我不確定,房間很大,最後大概有 200 人左右到場。那個會場在走廊最末端,你得一路走到走廊盡頭才能到。沒錯,大概有 200 人左右參加了那場會議,並聽到了多位醫師與 KOL 醫師帶來的精彩演講。所以那真的是一個非常、非常棒的活動。我認為這也大致反映了整體的關注度。
We're still a small player in the EP field, but there is a renewed interest from many physicians who long have thought that robotics was an old technology and a stale technology and are interested and kind of starting to recognize that the technology that they remembered is not anymore how it is today and the opportunity is there for them to actually engage with us in a much more meaningful way. So that was one of the highlights, obviously, over the last few weeks as the whole HRS conference, and then specifically the SCRN session there.
我們在 EP(電生理)領域仍然是個小型參與者,但許多醫師重新燃起興趣;他們長期以來認為機器人是老舊且缺乏新意的技術,如今開始有興趣並逐漸認知到,他們記憶中的那套技術已不再是今天的樣貌,而他們確實有機會以更有意義的方式與我們合作。因此,這是過去幾週的一個亮點——不只是整個 HRS 會議,尤其是其中的 SCRN 場次。
If we look at PFA specifically, I know I didn't include any discussions about that in the prepared remarks, not because there's anything negative just because we're continuing, as we've discussed in the March call, and we had enough other things to speak about on this call. We're still working, obviously, with CardioFocus -- we have announced collaboration. We're working on the effort of getting compatibility between MAGiC and CardioFocus' generator, PFA generator approved in Europe. We've done kind of meaningful work and started actually the kind of regulatory engagement with a notified body.
若特別看 PFA,我知道我在事先準備的講稿中沒有提到,並不是因為有任何負面因素,而是因為我們正如在 3 月電話會議中所討論的那樣持續推進,而且這次電話會議還有足夠多其他事項要談。我們仍在與 CardioFocus 合作——我們已宣布合作關係。我們正在推動讓 MAGiC 與 CardioFocus 的產生器相容,也就是其在歐洲獲批的 PFA 產生器。我們已完成相當有意義的工作,並且實際上已開始與公告機構(notified body)進行法規層面的互動。
And so that's kind of clearly underway. We also have kind of another collaboration, one of those that we've kind of not mentioned the name, but discussed over the last couple of years. And that is also overall a clear opportunity for leveraging a variant of MAGiC with their generator. And so we continue to view that kind of as an exciting space. I think during the talks, the physician talks at the SCRN symposium, there was a few kind of where the speakers were noting how despite all of the enthusiasm for PFA, there is still various safety signals that things like stability of the catheter with the tissue are particularly important for PFA, both efficacy and safety.
因此這項工作顯然正在進行中。我們也有另一項合作——這是我們過去幾年提過但未公開名稱的合作之一。整體而言,這也提供了明確的機會,能以 MAGiC 的某個變體與對方的產生器搭配運用。因此我們仍將其視為令人振奮的領域。我想在 SCRN 研討會的醫師演講中,有幾位講者提到,儘管大家對 PFA 充滿熱情,但仍存在各種安全訊號;例如導管與組織接觸的穩定性,對 PFA 的療效與安全性都特別重要。
Our stability of the catheter is one of our hallmarks of our catheter and a great benefit there. And then as you start to think about PFA in the ventricle, we have an ability to obviously get anywhere in the ventricle to stay steady on that tissue. And so we're probably in a very, very good position. And some of the speakers there weren't part of our animal studies. And so they, I believe, shared data from those animal studies in their presentations.
我們導管的穩定性是其標誌性特點之一,也是在這方面的一大優勢。再者,當你開始思考在心室進行 PFA 時,我們顯然具備到達心室任何位置並在該組織上保持穩定的能力。因此我們可能處於非常、非常有利的位置。而且那裡的一些講者並未參與我們的動物研究;所以我相信他們在簡報中分享了那些動物研究的數據。
On the ASC side, the ASC side is fascinating. It's obviously still a minority, right? The vast majority of cardiac ablation procedures are still done in the hospital setting, but you've seen in several states ASC starting to get set up to do cardiac ablation procedures. There's obviously the precedent in many other areas of medical devices where ASCs have kind of become a dominant setting for procedures.
至於 ASC 方面,ASC 這一端非常有意思。它顯然仍是少數,對吧?絕大多數心臟消融手術仍在醫院環境中進行,但你已經看到在若干州開始設立 ASC 來執行心臟消融手術。當然,在許多其他醫療器材領域也有先例,ASCs 已逐漸成為手術的主要場域。
We think and believe that the robot, the Stereotaxis robot should be very well suited for the ASC, particularly because of our safety profile. And that's obviously one of the biggest risks from moving from the hospital setting to the ASC setting is that you don't have the same safety net in terms of all of the hospital resources around you.
我們認為並相信,Stereotaxis 機器人非常適合 ASC,特別是因為我們的安全性表現。從醫院場景轉移到 ASC 場景最大的風險之一,就是你周遭不再擁有同等的醫院資源作為安全後盾。
And so we think that our robot can provide a big benefit there. The vast majority of procedures currently being done in the ASC setting are paroxysmal AF. That's not where our robot shines. Our robot can shine in things like PVCs and in various other areas where stability and safety and navigation is more challenging. And so I very much hope, believe that one of those GenesisX installations this year will be in the ASC setting, and that will start to demonstrate also the financial and clinical merit of having a robot in the ASC setting.
因此我們認為機器人能在那裡帶來很大的效益。目前在 ASC 場景中進行的手術大多是陣發性房顫(paroxysmal AF)。那並不是我們機器人最擅長的領域。我們的機器人更能在例如 PVC(心室早期收縮)以及其他需要更高穩定性、安全性與導航能力、操作更具挑戰性的領域發揮所長。因此我非常希望、也相信,今年的 GenesisX 裝機中會有一套是在 ASC 場景,並開始展示在 ASC 配置機器人的財務與臨床價值。
Again, this is small. This is something that will be a long-term tailwind to it in the US, but I definitely think there's merit to us being there early on and starting to demonstrate the value there. And hopefully, that will give us another opportunity over the next few years to grow kind of and to help the ASC setting grow as a field for cardiac ablation.
再次強調,這目前規模不大。在美國,這會是一個長期的順風因素,但我確實認為我們提早進入、開始展示其價值是有意義的。也希望這能在未來幾年為我們帶來另一個成長機會,同時也協助 ASC 場景作為心臟消融領域的一部分持續成長。
Operator
Operator
There are no further questions at this time. I will now turn the call back to David Fischel for closing remarks.
目前沒有其他問題。我現在把電話交回給 David Fischel 作結語。
David Fischel - Chairman of the Board, Chief Executive Officer
David Fischel - Chairman of the Board, Chief Executive Officer
Okay. Thank you very much for your questions and for your continued support. We look forward to hosting the investors visiting our office on Thursday for our Annual Shareholder Meeting, and we will continue working hard for your benefit and look forward to speaking again soon. Thank you very much.
好的。非常感謝各位的提問以及持續的支持。我們期待在週四於年度股東大會時接待前來我們辦公室參訪的投資人;我們也將持續努力,為各位創造利益,並期待很快再次與各位交流。非常感謝。
Operator
Operator
This concludes today's call. Thank you for attending. You may now disconnect.
今天的電話會議到此結束。感謝各位參與。您現在可以掛線。